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The chemokine RANTES is critically involved in neuroinflammation
and has been implicated in the pathophysiology of multiple scle-
rosis. We examined the possibility that activation of G-protein-
coupled metabotropic glutamate (mGlu) receptors regulates the
formation of RANTES in glial cells. A 15 hr exposure of cultured
astrocytes to tumor necrosis factor- and interferon- induced a
substantial increase in both RANTES mRNA and extracellular
RANTES levels. These increases were markedly reduced when
astrocytes were coincubated with L-2-amino-4-phosphono-
butanoate (L-AP-4), 4-phosphonophenylglycine, or L-serine-O-
phosphate, which selectively activate group III mGlu receptor
subtypes (i.e., mGlu4, -6, -7, and -8 receptors). Agonists of
mGlu1/5 or mGlu2/3 receptors were virtually inactive. Inhibition of
RANTES release produced by L-AP-4 was attenuated by the
selective group III mGlu receptor antagonist (R,S)--methylserine-
O-phosphate or by pretreatment of the cultures with pertussis
toxin. Cultured astrocytes expressed mGlu4 receptors, and the
ability of L-AP-4 to inhibit RANTES release was markedly reduced
in cultures prepared from mGlu4 knock-out mice. This suggests
that activation of mGlu4 receptors negatively modulates the pro-
duction of RANTES in glial cells. We also examined the effect of
L-AP-4 on the development of experimental allergic encephalo-
myelitis (EAE) in Lewis rats. L-AP-4 was subcutaneously infused
for 28 d by an osmotic minipump that released 250 nl/hr of a
solution of 250 mM of the drug. Detectable levels of L-AP-4 (100
nM) were found in the brain dialysate of EAE rats. Infusion of
L-AP-4 did not affect the time at onset and the severity of neuro-
logical symptoms but significantly increased the rate of recovery
from EAE. In addition, lower levels of RANTES mRNA were found
in the cerebellum and spinal cord of EAE rats infused with L-AP-4.
These results suggest that pharmacological activation of group III
mGlu receptors may be useful in the experimental treatment of
neuroinflammatory CNS disorders.
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Chemokines constitute a growing family of low molecular weight
cytokines (8–14 kDa) that play a pivotal role in many biological
processes, from routine immunosurveillance to the control of
inflammation and cell infection by human immunodeficiency vi-
rus. They are divided into four distinct subfamilies (designated as
 or CXC,  or CC,  or CX3C, and  or C chemokines) and
activate G-protein-coupled receptors, which are named according
to the classification of their specific ligands (Bazan et al., 1997;
Pan et al., 1997; Wells et al., 1998). Chemokines have been
implicated in the modulation of numerous biological functions in
both the developing and mature CNS, including neuropoiesis,
oligodendrocyte proliferation, regulation of synaptic plasticity,
and, particularly, leukocyte recruitment in response to traumatic
injury, stroke, autoimmunity, and inflammation (Mennicken et
al., 1999). Chemokines are the only group of inflammatory me-
diators endowed with cell type-selective chemotactic activity, and
hence, they play a vital role in defining the cellular composition of
inflammatory infiltrates at the sites of tissue damage. Because of
this, chemokines are becoming potential targets for therapeutic
intervention in inflammatory disorders of the CNS, including
multiple sclerosis (MS) (Godiska et al., 1995; Miyagishi et al.,
1997; Ransohoff and Bacon, 2000) (see Discussion and references
therein). Chemokines are constitutively expressed at low-to-
negligible levels in neurons, astrocytes, and microglia, but are
markedly upregulated in response to proinflammatory cytokines,
such as tumor necrosis factor- (TNF-) and interferon-
(IFN-) (Barnes et al., 1996; Mennicken et al., 1999). The iden-
tification of membrane receptors that control the induction of
chemokines is an obligatory step in the search for drugs acting on
leukocyte recruitment in neuroinflammation. We now report that
pharmacological activation of group III mGlu receptors reduces
the synthesis and release of the -chemokine RANTES (from
regulated upon activation of normal T cell expressed and se-
creted) induced by TNF- and IFN- in cultured astrocytes and
increases the rate of functional recovery in an in vivo model of
neuroinflammation.
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MATERIALS AND METHODS
Materials. (S)-4-carboxy-3-hydroxyphenylglicine (4C3HPG), L-2-amino-
4-phosphonobutanoate (L-AP-4), (R,S)--methylserine-O-phosphate
(MSOP), L-serine-O-phosphate (L-SOP), (RS)-3,5-dihydroxyphenylgly-
cine (DHPG), and (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-
APDC) were purchased from Tocris Cookson Ltd. (Bristol, UK).
4-phosphonophenylglycine (PPG) was a generous gift from Dr. Peter J. Flor
and Dr. Fabrizio Gasparini (Novartis Pharma, Basel, Switzerland). All
other drugs or chemicals were purchased from Sigma (Milan, Italy).
Preparation of primary cultures of mouse or rats cortical astrocytes.
Primary cultures of cortical astrocytes were prepared from neonate CD1
mice (Charles River, Calco, Italy), mGlu4 knock-out mice (Jackson
Laboratories, Bar Harbor, MN), or Lewis rats (Charles River), as
described by Rose et al. (1992). Dissociated cortical cells were grown in
MEM–Eagle’s salts, supplemented with 10% horse serum, 10% fetal calf
serum, 2 mM glutamine, 25 mM sodium bicarbonate, and 21 mM glucose.
Cultures were kept at 37°C in a humidified 5% CO2 atmosphere until
they reached confluence (7–14 d in vitro). The number of microglial cells
contaminating the cultures was assessed in cultures fixed with 2% para-
formaldehyde by using the lectin, isolectin B4 Banderiera simplicifolia I,
coupled to biotin. After 30 min of incubation at room temperature with
lectin at 1:50 dilution, lectin binding was identified by using the ABC
Vectastain kit (Vector Laboratories, Burlingame, CA). The efficacy of
the method for the detection of microglial cells was proven by staining
spinal cord sections of Lewis rats 11 d after immunization with myelin
basic protein (MBP) (data not shown).
Measurement of extracellular RANTES in the glial medium. Glial cul-
tures were washed with serum-free medium and, 1 hr later, were incu-
bated for 15 hr with IFN- (10 U/ml) and TNF- (0.1 ng/ml), in the
absence or presence of specific mGlu receptor ligands. At the end of the
incubation, the medium was removed and used for the determination of
RANTES using the mouse RANTES QUANTIKINE M immunoassay
ELISA kit (R & D Systems, Minneapolis, MN).
RNA extraction and Northern blot analysis of RANTES mRNA. Total
RNA was prepared from cultured astrocytes and from cerebellum and
spinal cord of Lewis rats (Chomczynski and Sacchi, 1987). Thirty mi-
crograms of total RNA were denatured, subjected to electrophoresis on
1% formaldehyde agarose gel, and transferred to a nylon membrane
Hybond-N (Amersham Pharmacia Biotech, Milan, Italy). Membranes
were fixed by UV irradiation using an XL-1500 UV cross-linker (Spec-
trolinker, Spectronics Corporation, Westbury, NY) and stained with
0.04% methylene blue and 0.5 M sodium acetate. Membranes were
hybridized with a random primed [- 32P]-dCTP-labeled probe consist-
ing of RANTES 0.7 kb cDNA insert in a pCR II vector (Invitrogen,
Groningen, The Netherlands) cloned at the BstXI/NotI site. Hybridiza-
tions were performed overnight at 42°C. Blots were washed twice using
2 SSC–0.1% SDS for 15 min at 42°C and then twice with 0.1
SSC–0.1% SDS for 15 min at 42°C. The filters were then exposed to
Hyperfilm-MP (Amersham Pharmacia Biotech) and exposed at 80°C
for 18 hr. Filters were reprobed with -actin cDNA, and autoradiograms
were quantified by densitometry using a computerized image-processing
system (NIH Imaging, Bethesda, MD).
RT-PCR analysis of mGlu4 receptors. Two micrograms of total RNA
extracted from cultured astrocytes and 100 ng of random hexamers
dissolved in 10 l of RNase-free water were heated to 65°C for 10 min
and then cooled on ice. Reverse transcriptase (RT) buffer (10 mM DTT,
500 M dNTP, and 200 U of Moloney murine leukemia virus RT
enzyme) was added to a final volume of 25 l. The incubation was
continued at 42°C for 1 hr, and the reaction was terminated by a 10 min
incubation at 99°C. PCR was performed for 35 cycles in final volume of
50 l with appropriate quantity of buffer and MgCl2, 200 M of dNTP,
50 pmol of either forward or reverse primers, and 2.5 U of AmpliTaq
Gold (Perkin-Elmer Cetus Corp., Norwalk, CT). RT-PCR negative
control was performed loading dH2O instead of cDNA. Primers and
PCR conditions were as follows: mGlu4 receptor: GenBank accession
#M90518; 1.5 mM MgCl2; annealing at 60°C; amplimer 567 bp; forward:
5-TGAGCTACGTGCTGCTGGCG-3; reverse: 5-TGTCGGCTGA-
CTGTGAGGTG-3.
Western blot analysis of RANTES and mGlu4 receptors. Western blot
analysis in protein extracts from lysates of cultured astrocytes prepared
from mice or rats or from mouse cerebral cortex (used as a positive
control) was performed as described by Ciccarelli et al. (2000). RAN-
TES expression was detected with 4 g/ml of a monoclonal antibody (R
& D Systems). mGlu4a receptors were detected with 0.5 g/ml of a
polyclonal antibody raised against synthetic peptides corresponding to
the following amino acid sequences CGGLETPALATKQTYVTNHAI
corresponding to the putative intracellular C-terminal domain of rat
mGlu4a receptor (Upstate Biotechnology, Inc. Lake Placid, NY; resi-
dues 893–912) (Bradley et al., 1996, 1999).
Induction of experimental allerg ic encephalomyelitis in Lewis rats. For
experimental allergic encephalomyelitis (EAE) induction, Lewis rats
(225–250 gm, body weight) were immunized in the proximal portion of
the tail with 50 g of guinea pig MBP, 2 mg Mycobacterium tuberculosis
in 100 l saline, and 100 l Freund’s incomplete adjuvant. Animals were
implanted with subcutaneous osmotic minipumps (Alzet; Alza, Palo
Alto, CA) containing 200 l of 250 mM of L-AP-4 dissolved in PBS, which
release 250 nl /d for 28 d. Control animals were implanted with
minipumps containing PBS alone. Immunization was performed 48 hr
after implanting the osmotic minipumps. In standard experiments, im-
munized animals developed clinical signs of EAE 10 d after immuniza-
tion. Symptoms of EAE were scored using the disability scale described
by Godiska et al. (1995) in which 0  absence of clinical signs; 1  loss
of motor control in the tail; 2  hindquarter weakness or the inability to
turn over when placed on the back; 3  total hindquarter paralysis; 4 
total hindquarter paralysis with incontinence and/or forearm involve-
ment; and 5  death caused by EAE. In addition, body weight was
monitored every day during the development of EAE.
Some animals were killed 12 d after immunization (i.e., at the time of
the peak of clinical symptoms) for the detection of RANTES in the
cerebellum and spinal cord. RANTES protein and mRNA levels were
assessed by Western and Northern analysis, as described above.
Immunohistochemical analysis of spinal cords. Two established param-
eters of neuroinflammation, i.e., the expression of major histocompati-
bility complex (MHC) class II antigens and the presence of CD4 cells
were examined by immunohistochemistry in Lewis rats immunized with
MBP and treated with L-AP-4, as described above. Animals were killed
by CO2 inhalation at 11 or 27 d after immunization, and spinal cords
were collected and snap-frozen in liquid nitrogen. For immunohisto-
chemical analysis, spinal cord cryostat sections (10 m) were exposed to
appropriate dilutions of the mouse FITC-conjugated monoclonal anti-
bodies (Seralab, Crawley-Down, UK) directed against the rat homologs
of human CD4, (W3/25), and MHC class II antigens (OX6). Coded slides
were examined by fluorescence microscopy at 40 magnification. Inflam-
mation grade was assessed blindly and scored from grade 1–4 in relation
to the intensity of immunostaining, density of immunopositive cells, and
distribution of clusters of immunopositive cells (total score: 0–12) (Di
Marco et al., 2001).
Measurements of L-AP-4 levels by in vivo microdialysis. To assess
whether subcutaneously infused L-AP-4 can penetrate the brain, we
measured the amount of the drug present in the striatal dialysate of freely
moving animals. Lewis rats, 250–300 gm, were implanted with microdi-
alysis intracerebral guides in the striatum using the following coordi-
nates: 2.0 mm anterior to bregma, 2.6 mm lateral to the midline, and 4–6
mm ventral, according to the atlas of Pellegrino et al. (1992), under
pentobarbital anesthesia (50 mg/kg, i.p.). After surgery, rats were housed
in separate cages in a temperature-controlled environment on a 12 hr
light /dark cycle, with ad libitum access to water and food, and allowed to
recover. Forty-eight hours later rats were implanted with subcutaneous
osmotic minipumps (Alzet), containing L-AP-4 (200 l, 250 mM) that
release 250 nl /d for 28 d of L-AP-4, and were immunized 48 hr later as
described above. Microdialysis was performed 9 d after immunization.
Twelve hours before the experiment, a concentric vertical probe (2-mm-
long and 0.5 mm in outer diameter having a polycarbonate membrane;
molecular cutoff: 20,000 Da; CMA/12; CMA Microdialysis, Stockholm,
Sweden) was inserted into the intracerebral guide cannula, and rats were
transferred to a plastic bowl cage with a moving arm. The animals had ad
libitum access to water and food. The probe was perfused continuously
with artificial CSF (ACSF), at a flow rate of 0.1 l /min, using a micro-
injection pump. ACSF contained in mM: 150 NaCl, 3 KCl, 1.7 CaCl2,
and 0.9 MgCl2. On the next day, perfusate sample fractions were con-
tinuously collected by a fraction collector. Analysis of L-AP-4 present in
the dialysate was performed by HPLC with fluorescence detection.
Measurement of extracellular RANTES in leukocytes. Peripheral blood
mononuclear cells (PBMCs) were prepared using Ficoll HyPaque ac-
cording to the manufacturer’s recommended protocol. Enriched mono-
cytes were obtained from whole PBMCs by incubation with RPMI 1640
 10% FCS at 4°C, for 30 min at constant rotation. Nonaggregated cells
were removed, and monocyte-enriched pellet was resuspended in RPMI
and plated 2 106 cells per well in 6-well plates. After a 2 hr incubation
at 37°C, nonadherent cells were removed, and adherent cells were
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washed. Adherent cells were then removed from the plate using trypsin.
This enriched monocyte fraction was 85–90% CD4 by flow cytometric
analysis. CD8 cells were obtained from whole PBMCs by negative
selection. Briefly, cells were incubated with an antibody cocktail contain-
ing microbeads against CD4, 11b, 14, 16, 19, 36, 56, and IgE (Miltenyi
Biotec) for 30 min at 4°C. Cells were washed and passed over a perma-
nent magnet. The negative fraction was 95% CD8 as determined by
flow cytometric analysis. Cells were preincubated with appropriate con-
centration of L-AP-4 for 30 min at 37°C and seeded at 2  10 5 cells per
well in 96-well plates. Phorbol-12-myristate-13-acetate (PMA) was
added, and cultures were incubated for 48 hr at 37°C. Supernatants were
collected and stored at 80°C. For the determination of extracellular
RANTES, human anti-RANTES antibody (Genzyme Techne) was
coated on a 96-well plate (10 g/ml) at 4°C for 18 hr. Plate was washed
three times with PBS. Nonspecific sites were blocked by an incubation
with PBS supplemented with 5% BSA. After washing plate with PBS 
0.05% Tween 20, 50 l /well supernatant was added and incubated at
room temperature for 2 hr. A Europium-labeled anti-RANTES antibody
was added (a kind gift from H. Inbe, Department of Biological Chemis-
try, Yamaguchi University, Yamaguchi, Japan) and incubated for a
further 2 hr at room temperature. Plate was washed using PBS  0.05%
Tween 20 at 300 l /well. Enhancement solution (LKB-Wallac, Gaith-
ersburg, MD) was added at 100 l /well and incubated at room temper-
ature for 10 min. The plate was then measured for Europium counts
using a Wallac Arvo SX Multi-Label counter (Wallac).
RESULTS
Activation of group III mGlu receptors reduces the
production of RANTES in primary cultures of glial cells
We used confluent cultures of glial cells, which were primarily
constituted of flat and polygonal type-1 astrocytes. Cultures were
virtually devoid of microglial cells (only 6–10 cells per well
stained with the lectin, Banderiera simplicifolia I). A 15 hr expo-
sure of mouse cultured glial cells to 0.1 ng/ml of TNF- plus 10
U/ml of IFN- led to a substantial increase in the amount of
RANTES released into the medium. L-AP-4 applied in combi-
nation with TNF- and IFN- reduced extracellular RANTES
levels in a concentration-dependent manner, with an apparent
EC50 value of 6 M (Fig. 1A). Among other mGlu receptor
ligands, L-SOP (300 M) and PPG (100 M) were also able to
reduce extracellular RANTES. 4C3HPG, 2R,4R-APDC, and
DHPG (all at 100 M) had negligible, if any, effect on the
cytokine-stimulated increase in extracellular RANTES (Fig.
1B). The group III mGlu receptor antagonist MSOP (100 M)
produced a slight increase in extracellular RANTES on it own,
but markedly reduced the inhibitory action of L-AP-4 (30 M)
(Table 1). None of the mGlu receptor ligands induced changes in
extracellular RANTES in the absence of TNF- and IFN-
(data not shown). We also assessed intracellular RANTES
mRNA and protein levels in mouse cultured glial cells. Northern
blot analysis showed that RANTES mRNA levels were nearly
undetectable in untreated cultures but increased substantially
after a 15 hr treatment with TNF- and IFN-. This increase was
markedly reduced by L-AP-4 (100 M) or PPG (100 M), but was
minimally affected by 2R,4R-APDC (100 M) or DHPG (100 M)
(Fig. 2A,B). Similarly, L-AP-4 reduced the cytokine-induced in-
crease in RANTES protein levels, and its action was attenuated
in cultures pretreated with pertussis toxin (PTX) (Fig. 3).
Finally, we measured the ability of L-AP-4 to reduce cytokine-
stimulated RANTES production in cultured glial cells prepared
from knock-out mice lacking mGlu4 receptors. In mGlu4(/)
cultures a 15-hr treatment with TNF-  IFN- increases the
extracellular levels of RANTES to the same extent as in cultures
from wild-type mice. L-AP-4 could still reduce cytokine-
stimulated RANTES release in mGlu4(/) cultures, but only at
concentrations of 300 M (Fig. 1A).
Figure 1. Extracellular RANTES levels in mouse cultured astrocytes
exposed to TNF- and IFN- in the absence or presence of mGlu
receptor ligands. A, Concentration-dependent effect of L-AP-4 on the
increase in extracellular RANTES induced by TNF- and IFN- in
cultured cortical astrocytes prepared from wild-type or knock-out mouse
cortical astrocytes. Addition of TNF- and IFN- increased extracellular
RANTES levels from 0.15  0.02 to 6.7  0.81 ng/mg protein in
wild-type cultures and from 0.08  0.04 to 5.9  0.63 ng/mg protein in
mGlu4(/) cultures. Values were calculated as a percentage of
cytokine-stimulated RANTES release and represent the means  SEM
of six determinations. *p 	 0.05 (one-way ANOVA  Fisher’s PLSD) as
compared with TNF- and IFN- alone. B, Effect of different mGlu
receptor ligands on the increase in extracellular RANTES induced by
TNF- and IFN- in mouse cultured astrocytes. Values were calculated
from 6–12 determinations from at least three individual multiplates. All
mGlu receptor ligands were added at concentrations of 100 M with the
exception of L-SOP (300 M). *p 	 0.05 (one-way ANOVA and Fisher’s
PLSD) as compared with values obtained in the absence of mGlu recep-
tor ligands ().
Table 1. MSOP antagonizes the reduction in extracellular RANTES
levels induced by L-AP4
ng/mg prot.
TNF-  IFN- 7.14  0.66
 L-AP4, 30 M 3.56  0.12*
 MSOP, 100 M 8.53  0.38
 L-AP4  MSOP 9.17  1.42
Values are means  SEM of four individual determinations.
*p 	 0.05 (one-way ANOVA  Fisher’s PLSD) compared with all other groups.
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Detection of mGlu4 receptors in cultured glial cells
In immunoblots, mGlu4 antibodies labeled a major band at 100
kDa, which corresponds to the receptor monomer. This band was
detected in cultured glial cells from wild-type mice or Lewis rats,
but not in cultures from mGlu4(/) mice (Fig. 4A). The pres-
ence of mGlu4 receptors in cultured glial cells was confirmed by
RT-PCR analysis (Fig. 4B).
Effect of L-AP-4 on the development of EAE in
Lewis rats
To assess whether the modulation of RANTES formation in glial
cells has any functional relevance, we examined the effect of
systemically injected L-AP-4 in the EAE model of neuroinflam-
Figure 3. Western blot analysis of RANTES in mouse cultured astro-
cytes incubated for 15 hr with TNF- and IFN- in the absence or
presence of L-AP-4 (100 M) and/or PTX (0.5 g/ml, preincubated for 16
hr before the incubation with the cytokines). Note that PTX abolished
the reduction in RANTES levels induced by L-AP-4.
Figure 4. Expression of mGlu4a receptor in cultured astrocytes. A,
Western blot analysis of mGlu4a receptor in cultured astrocytes from
wild-type mice, mGlu4(/) mice, or Lewis rats. Expression in the
cerebral cortex of wild-type mice is shown as a positive control. The
antibody recognized a specific band corresponding to the monomeric
form of receptor at 100 kDa (arrow). B, RT-PCR analysis of mGlu4a
receptor mRNA in cultured astrocytes from wild-type mice or Lewis rats.
() and () refer to the absence or presence of reverse transcriptase.
Mouse cerebral cortex is shown as reference tissue. NC represents a
negative control in which dH2O has been loaded instead of cDNA. Size
markers ( M ) are on the last lane on the right.
Figure 2. RANTES mRNA levels in mouse cultured astrocytes incu-
bated for 15 hr with TNF- and IFN- in the absence or presence of
different mGlu receptor agonists. A, Representative Northern Blot of
RANTES mRNA in mouse cultures of astrocytes. In the first lane, the
spleen is shown as a positive control. Note that RANTES mRNA levels
were nearly undetectable in untreated cultures (), but increased sub-
stantially after a 15 hr treatment with TNF- and IFN-. This increase
was markedly reduced by L-AP-4 or PPG (both at 100 M). B, Densito-
metric analysis of RANTES mRNA levels in cultured astrocytes incu-
bated for 15 hr with TNF- and IFN- in the absence or presence of
4C3HPG, 2R,4R-APDC (APDC), L-AP-4, or PPG (all at 100 M). Values
were normalized by the amount of -actin mRNA and represent the
means  SEM of three determinations. *p 	 0.05 (one-way ANOVA plus
Fisher’s PLSD) versus cultures treated with TNF- and IFN- alone ().
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mation in Lewis rats. Immunization of Lewis rats with guinea pig
MBP induced the classical symptoms of EAE after a latency of
10 d, as assessed by the disability scale and by the loss of body
weight. In standard experiments, the course of EAE was biphasic,
showing a peak at 11–13 d after immunization, followed by a drop
in the score during days 14–18 and by a plateau phase with scores
of 1–1.5 lasting until day 23. No relapses were observed after full
recovery of EAE. Figure 5 shows the temporal profile of EAE in
control rats and in rats implanted with a subcutaneous osmotic
minipump releasing 250 nl/d of a PBS solution containing 250 mM
of L-AP-4. The pump was implanted 2 d before immunization.
Detectable amounts of L-AP-4 (105  37 nM; n  3) were
detected in the striatal dialysate of freely moving rats, suggesting
that some amounts of subcutaneously infused L-AP-4 can pene-
trate the brain. No gross abnormalities in motor behavior were
observed in nonimmunized rats treated with L-AP-4 or in immu-
nized rats infused with L-AP-4 before the clinical onset of EAE,
as detected by measuring locomotor activity in an open field
apparatus (data not shown). In rats treated with L-AP-4 there was
no difference in the time at onset and in the peak of the disability
score of EAE, as compared with control rats implanted with a
minipump containing PBS alone, although L-AP-4-treated rats
reached the peak of the disability score 1 d later than control rats
(i.e., 12 instead of 11 d after immunization). However, rats
treated with L-AP-4 showed a faster recovery rate from EAE, as
indicated by the absence of the plateau phase, and showed a full
recovery after 19 d (vs 24 or 25 d in control rats) (Fig. 5A,B).
Independent groups of animals were used for histological exam-
ination. Neuroinflammation was assessed by immunohistochemi-
cal analysis of MHC-II and CD4 cells in the spinal cord
(MHC-II cells in the spinal cord of immunized animals are
shown in the lower panel of Fig. 6A). We adopted a semiquanti-
Figure 5. Effect of L-AP-4 on the development of
EAE in Lewis rats. A, Temporal profile of body
weight in animals immunized with MBP implanted
with an osmotic minipump, which released 250 nl/d
of PBS or a PBS solution containing 250 mM of
L-AP-4. B, Temporal profile of the disability score of
EAE. Note that rats treated with L-AP-4 showed a
faster recovery rate from EAE than control rats.
Values express the means  SEM of 10 animals per
group. *p 	 0.05 (one-way ANOVA and Fisher’s
PLSD) versus PBS-treated animals.
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tative scale with scores from 0 to 4 referred to the intensity of
staining, number of immunopositive cells within identified clus-
ters of cells, and distribution of clusters of immunopositive cells
(maximal score  12; modified from Di Marco et al., 2001).
Animals were examined at day 11 or 27 after immunization. A
substantial increase in the neuroinflammation score for both
MHC-II and CD4 was observed in the spinal cord of immunized
animals after 11 d, i.e., at the time of the peak of motor symp-
toms. The score was only slightly reduced at 27 d, when animals
were apparently asymptomatic (Fig. 6B–D). Immunized rats that
received L-AP-4 subcutaneously had a lower disability score at
day 11 (Fig. 6B) and a lower number of MCH-II cells in the
spinal cord (Fig. 6C). The MCH-II score showed a trend to a
reduction also at 27 d in immunized animals treated with L-AP-4
(Fig. 6C). This trend with L-AP-4 was also observed by scoring
CD4 immunoreactivity at 11 and 27 d after immunization (Fig.
6D). In other animals we measured RANTES mRNA levels in
the cerebellum and spinal cord at the time of the peak of the
disability score. Northern blot analysis showed that treatment
with L-AP-4 reduced RANTES mRNA levels in the cerebellum
and spinal cord of EAE rats (Fig. 7). Because systemically in-
jected L-AP-4 gave only a partial protection against EAE, we
decided to examine whether the drug had any effect on the
production of RANTES by other cells that contribute to the
pathophysiology of EAE, such as leukocytes. Experiments were
performed on human purified protein derivative-derived Th1
clones, CD8 leukocytes, and monocytes, in which the produc-
tion and release of RANTES was stimulated by PMA (0.1–10
ng/ml). Addition of L-AP-4 (0.1–1000 M) had no effect on
extracellular RANTES in Th1 clones and showed a trend to
reduction of extracellular RANTES in CD8 cells and mono-
cytes. However, this trend was observed only with high concen-
trations of L-AP-4 (100 or 1000 M) and was not statistically
significant (Fig. 8A–C).
DISCUSSION
RANTES is a  chemokine that is gaining more and more
interest for its role in neuroinflammation. Similar to monocyte
chemoattractant protein-1 (MCP-1) and interferon--inducible
protein-10 (IP-10), RANTES is chemoattractant for monocytes,
and contributes to the pathophysiology of immune disorders,
including MS (Ransohoff, 1999). RANTES can also attract mem-
ory T and NK cells, which are involved in MS, and act as an
antigen-independent activator of T cells in vitro (Schall et al.,
1990; Bacon et al., 1995; Taub et al., 1995). In EAE, RANTES
amplifies the inflammatory process, and its expression correlates
with the intensity of neuroinflammation (Glabinski et al., 1998;
Ransohoff, 1999). In addition, RANTES has been associated
with the early formation of plaques (Simpson et al., 1998), and the
RANTES receptor CCR5 has been found in lymphocytes and
phagocytes of actively demyelinating lesions in MS (Bacon and
Oppenheim, 1998; Sorensen et al., 1999). Interestingly, the pro-
duction of RANTES by peripheral mononuclear cells is reduced
after treating MS patients with IFN--1b (Iarlori et al., 2000;
Zang et al., 2001), suggesting that the modulation of RANTES
production may be a valuable target in the pharmacological treat-
ment of MS patients. We examined the possibility that the pro-
duction of RANTES could be modulated by the activation of
glial membrane receptors. In particular, we focused on mGlu
receptors, which are G-protein-coupled receptors activated by
glutamate and other excitatory amino acids. mGlu receptors form
a family of eight subtypes, which are subdivided into three groups
on the basis of their sequence homology, pharmacological profile,
and transduction pathways. Group I includes mGlu1 and -5 re-
ceptors, which are coupled to inositol phospholipid hydrolysis and
activated by DHPG. Group II includes mGlu2 and -3 receptors,
which are coupled to Gi-proteins and activated by 2R,4R-APDC.
4C3HPG behaves as a mixed mGlu2/3 agonist /mGlu1 antagonist.
Group III includes mGlu4, -6, -7, and -8 receptors, which are also
coupled to Gi-proteins and selectively activated by L-AP-4, PPG,
and L-SOP (Pin and Duvoisin, 1995; Schoepp et al., 1999).
Whereas mGlu3 and -5 receptors are expressed by astrocytes
(Miller et al., 1995; Petralia et al., 1996; Ciccarelli et al., 1999),
evidence for the expression of group III mGlu receptors in glial
cells is still lacking. Hence, we used primary cultures of glial cells,
expecting that mGlu3 or -5 receptor agonists could modulate the
production of RANTES. Unexpectedly, however, only group III
Figure 6. Immunohistochemistry of MHC-II and CD4 cells in the
spinal cord of nonimmunized or immunized Lewis rats subcutaneously
infused with L-AP-4. An example of MHC-II immunostaining in the
spinal cord of nonimmunized (top panel ) and immunized (bottom panel )
rats is shown in A. The disability score of immunized animals killed at 11
or 27 d after MBP injection and used for immunohistochemical analysis
is shown in B (mean  SEM of three to five determinations; *p 	 0.05;
Student’s t test vs the respective group of rats subcutaneously infused with
saline). Quantification of MHC-II and CD4 immunostaining in nonim-
munized (untreated) or immunized (MBP) rats subcutaneously infused
with PBS or L-AP-4 is shown in C and D, respectively. Immunized rats
were examined at day 11 or 27 after injection of MBP. Untreated rats
were examined 13 d after implantation of osmotic minipumps releasing
either saline or L-AP-4. Values are means  SEM of three to five
determinations; *p 	 0.05 (one-way ANOVA and Fisher’s PLSD, as
compared with the respective group implanted with minipumps releasing
saline).
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mGlu receptor agonists (i.e., L-AP-4, PPG, or L-SOP) reduced
RANTES levels in cultures stimulated with TNF- and IFN-.
L-AP-4, the prototypic agonist of group III mGlu receptors,
produced the more substantial and reproducible effect on RAN-
TES levels, and its action was sensitive to the group III mGlu
receptor antagonist MSOP (Schoepp et al., 1999) and to PTX,
which inhibits the activity of Gi-proteins. The reduction of RAN-
TES mRNA levels by L-AP-4 or PPG suggested that these drugs
act at transcriptional level or decrease the stability of RANTES
mRNA. The calculated EC50 value for L-AP-4 is consistent with
the activation of mGlu4 or -8 rather than mGlu7 receptors, which
can be recruited only by concentrations of L-AP-4 100 M
(Schoepp et al., 1999). At least mGlu4 receptors appeared to be
expressed by cultured glial cells. It is unlikely that expression of
mGlu4 receptors derived from contaminating microglia, because
only 6–10 microglial cells per well were detected with a method
that was highly efficacious in detecting microglia in the inflam-
matory infiltrate of EAE rats (data not shown). In cultures from
mGlu4 knock-out mice, only concentrations of L-AP-4  100 M
were still able to reduce the production of RANTES. This
indicates that glial mGlu4 receptors primarily contribute to the
regulation of RANTES formation in astrocytes. Whether the
effect produced by 300 M L-AP-4 reflects the recruitment of
mGlu7 receptors or rather represents a nonspecific effect of the
drug remains to be determined. Moving from the in vitro data, we
decided to examine the effect of L-AP-4 on EAE in Lewis rats.
Because EAE develops gradually after a latency period of 10 d,
we continuously infused L-AP-4 by means of a subcutaneous
Figure 7. Expression of RANTES mRNA levels in the cere-
bellum and spinal cord of EAE rats subcutaneously infused with
PBS or L-AP-4. A, Densitometric analysis of RANTES mRNA
levels in the cerebellum and spinal cord is shown in A, and B,
respectively. Values were normalized by the amount of -actin
mRNA and express the means  SEM of three determinations.
*p 	 0.05 (one-way ANOVA and Fisher’s PLSD) versus treated
animals. Subcutaneous infusion of L-AP-4 in nonimmunized rats
did not induce changes in RANTES mRNA levels in the cere-
bellum and spinal cord (93  7.8% of controls in the cerebellum
and 137  28% of controls in the spinal cord, 13 d after implan-
tations of osmotic minipumps; n  4).
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osmotic minipump. We used this strategy because the increased
permeability of the blood–brain barrier during the development
of EAE (Perry et al., 1997) could allow a sufficient penetration of
L-AP-4 into the brain. To assess whether this assumption was
correct, we measured extracellular brain levels of L-AP-4 by in
vivo microdialysis. The amount of L-AP-4 found in the dialysate
(100 nM) suggests that concentrations of L-AP-4 in the range of
0.1–1 M should be present in the extracellular space. These
concentrations may be sufficient to activate mGlu4 receptors
(Schoepp et al., 1999). Infusion of L-AP-4 neither delayed the
time at onset nor reduced the severity of EAE symptoms, al-
though treated animals reached the peak of the disability score
1 d later. Interestingly, however, treatment with L-AP-4 increased
the rate of recovery from EAE. The second phase of motor
disability, which was present in animals infused with PBS from
day 18 to day 23 after immunization, was not observed in animals
that received L-AP-4. Because EAE in Lewis rats represents a
model of neuroinflammation, but not of demyelination, we sug-
gest that L-AP-4 infusion reduces the inflammatory infiltrate in
the brain parenchyma to an extent that does not prevent the
development of EAE but allows a faster recovery from the dis-
ease (Miyagishi et al., 1997). Accordingly, immunized animals
treated with L-AP-4 showed a reduced immunostaining for MHC
class II in the spinal cord and a trend to a reduction in CD4
immunostaining in the spinal cord at day 11 after immunization.
The partial reduction of RANTES mRNA levels produced by
L-AP-4 infusion in the cerebellum and spinal cord of EAE rats
might account for the 1 d delay in reaching the peak of the
disability score, the reduced extent of neuroinflammation, and
the lack of the delayed plateau phase of the disability score. The
possibility that the delayed plateau phase is sustained by the
release of RANTES from glial cells is interesting and deserves
further investigation. The lack of a more robust effect of L-AP-4
on EAE may reflect the inability of the drug to reduce the
production of RANTES from other cells that directly contribute
to the inflammatory infiltrate, such as leukocytes. Accordingly,
L-AP-4 did not reduce the release of RANTES stimulated by
phorbol esters in lymphocytes or monocytes, although a trend to
a reduction with high concentrations of L-AP-4 was seen in CD8
lymphocytes and in monocytes.
In conclusion, present results offer the first demonstration that
group III mGlu receptors are expressed and functional in glial
cells. The unexpected finding that activation of these receptors
reduces the production of RANTES in astrocytes suggests that
brain-permeable agonists may be useful in the experimental
treatment of neuroinflammatory disorders of the CNS. The po-
tential usefulness of group III mGlu receptor agonists in human
pathology awaits the demonstration that these drugs show good
safety and tolerability when systemically injected.
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